Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126-Reference-Cited by-同舟云学术

Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Fischer Kathryn¹,Nguyen Kimberly¹,LiWang Patricia J.¹²

Affiliation:

1. Molecular Cell Biology, University of California, Merced, Merced, California, USA

2. Health Sciences Research Institute, University of California, Merced, Merced, California, USA

Abstract

Griffithsin (Grft) is an antiviral lectin that has been shown to potently inhibit HIV-1 by binding high-mannose N-linked glycosylation sites on HIV-1 gp120. A key factor for Grft potency is glycosylation at N295 of gp120, which is directly adjacent to N332, a target glycan for an entire class of broadly neutralizing antibodies (bNAbs).

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01084-19

Reference118 articles.

1. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women

2. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges

3. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women